Analysts’ estimates

Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017.

Analysts’ Recommendations for AstraZeneca as of May 15

The above chart shows analysts’ recommendations for AstraZeneca stock over the last 12 months.

Analysts’ ratings

AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date. Analysts’ estimates show that the stock has the potential to return ~6.8% over the next 12 months. Analysts’ recommendations show a 12-month target price of $38.89 per share for the stock compared to its price of $36.42 on May 14.

Analysts’ recommendations

As of May 15, six analysts are tracking AstraZeneca’s ADR (American depositary receipt) listed on the NYSE. Three of these analysts recommend “strong buys” on AstraZeneca, while one recommends a “buy,” and two recommend “holds.” The consensus rating for AstraZeneca stands at 1.83, which represents a strong buy for momentum investors as well as long-term investors.

AstraZeneca stock is listed on the London Stock Exchange, where 31 analysts are tracking it. Of these, nine analysts have recommended “strong buys,” 13 have recommended “buys,” five have recommended “holds,” and four have recommended “sells,” as we can see in the graph above. The consensus rating for AstraZeneca stock is 2.13, which represents a moderate buy for long-term investors and value investors.

Valuation multiples

As of May 15, AstraZeneca is trading at a forward PE (price-to-earnings ratio) of 20.3x compared to the industry average of 13.7x. Also, the forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple for AstraZeneca is 14.2x compared to the industry average of 11.2x.

The BLDRS Europe Select ADR ETF (ADRU) holds 2.6% of its total investments in AstraZeneca’s ADR (AZN), 0.5% in Teva Pharmaceutical’s ADR (TEVA), 5.7% in Novartis’s ADR (NVS), and 2.8% in GlaxoSmithKline’s ADR (GSK).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Latest articles

The Hot Chips 31 Symposium started this week. Artificial intelligence was the hot topic among participants Intel, NVIDIA, and Advanced Micro Devices.

Today, Slack (WORK) opened 4.5% higher after MKM Partners analyst Rohit Kulkarni gave Slack stock a "buy" rating with a target price of $40.

Today, Aphria announced a deal with ParcelPal to deliver medical cannabis to patients. Also, Cole Cacciavillani's son has won a cannabis store license.

Today, IHS Markit released the US manufacturing PMI (purchasing managers’ index) data for August. The manufacturing PMI hit 49.9, down from 50.4 in July.

On May 1, smokable hemp will be banned in North Carolina. The state passed the North Carolina Farm Act, removing smokable hemp from its permissible list.

Chinese tech giant Tencent (TCEHY) posted better-than-expected Q2 earnings. Its revenue growth accelerated in Q2 due to a rebound in its gaming segment.